In targeted temperature management (TTM) postcardiac arrest, tighter temperature control is achieved with internal than external cooling, a study has shown. Moreover, internal cooling potentially results in better survival-to-hospital discharge outcomes and reduces cardiac arrhythmia complications in carefully selected patients as compared with normothermia.
Diastolic blood pressure (BP) shows utility as a predictor of cerebrovascular disease and Alzheimer’s disease pathology, such that increased diastolic BP is associated with increased white matter hyperintensities and reduced hippocampal volume, according to a study.
Discontinuation of antihypertensive drugs appears to have a detrimental effect, with a recent study reporting that the risk of acute myocardial infarction (AMI) substantially increases after more than 90 days of discontinuation.
Adding sitagliptin, a dipeptidyl peptidase 4 inhibitor (DPP-4), to usual care in patients with glycaemic equipoise does not increase the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), according to the TECOS* study.
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant reductions in major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk in the LEADER (Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcomes Results) trial.
Newer metabolic agents, including trimetazidine, represent ancillary forms of prophylactic antianginal therapy and may be useful in patients with stable coronary artery disease (SCAD) who are unsuitable for percutaneous or surgical revascularization, says a leading cardiologist at the recent AFCC 2016.
Cardiovascular magnetic resonance (CMR) is a stronger predictor of major adverse cardiovascular events (MACE) compared with single-photon emission computed tomography (SPECT), according to the CE-MARC* study.